Hein Sigmon (kendodenim3)

TERPRETATION Short, 6-month regimens of a mosaic HIV-1 prophylactic vaccine elicited robust HIV-specific immune responses that were similar to responses elicited by a longer, 12-month schedule. Preclinical data showed partial protective efficacy of one of the short vaccine regimens in rhesus monkeys. Further clinical studies are required to test the suitability of the shortened vaccine regimens in humans. Such shortened regimens would be valuable to increase vaccine delivery at the community level, particularly in resource-limited settings. FUNDING Ragon Institute (Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University; Cambridge, MA, USA) and Janssen Vaccines & Prevention (Leiden, Netherlands). BACKGROUND Patients with Ewing sarcoma or osteosarcoma have a median overall survival of less than 12 months after diagnosis, and a standard treatment strategy has not yet been established. Pharmacological inhibition of MET signalling and aberrant angiogenesis has shown promising results in several preclinical models of Ewing sarcoma and osteosarcoma. We aimed to investigate the activity of cabozantinib, an inhibitor of MET and VEGFR2, in patients with advanced Ewing sarcoma and osteosarcoma. METHODS We did a multicentre, single-arm, two-stage, phase 2 trial in patients with advanced Ewing sarcoma or osteosarcoma recruited from ten centres in the French Sarcoma Group. Key eligibility criteria were aged 12 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and documented disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1) before study entry. The number of previous lines of treatment was not limited. Patients received cabozantinib (adults 60 mg,bozantinib has antitumor activity in patients with advanced Ewing sarcoma and osteosarcoma and was generally well tolerated. Cabozantinib could represent a new therapeutic option in this setting, and deserves further investigation. FUNDING Institut Bergonié; French National Cancer Institute; Association pour la Recherche contre le Cancer. Research on how humans understand the relative magnitude of symbolic fractions presents a unique case of the symbol-grounding problem with numbers. Specifically, how do people access a holistic sense of rational number magnitude from decimal fractions (e.g. 0.125) and common fractions (e.g. 1/8)? Researchers have previously suggested that people cannot directly access magnitude information from common fraction notation, but instead must use a form of calculation to access this meaning. Questions remain regarding the nature of calculation and whether a division-like conversion to decimals is a necessary process that permits access to fraction magnitudes. To test whether calculation is necessary to access fractions magnitudes, we carried out a series of six parallel experiments in which we examined how adults access the magnitude of rational numbers (decimals and common fractions) under varying task demands. We asked adult participants to indicate which of two fractions was larger in three different conditions decimal-decimal, fraction-fraction, and mixed decimal-fraction pairs. Across experiments, we manipulated two aspects of the task demands. 1) Response windows were limited to 1, 2 or 5 s, and 2) participants either did or did not have to identify when the two stimuli were the same magnitude (catch trials). Participants were able to successfully complete the task even at a response window of 1 s and showed evidence of holistic magnitude processing. These results indicate that calculation strategies with fractions are not necessary for accessing a sense of a fractions meaning but are strategic routes to magnitude that participants may use when granted sufficient time. We suggest that rapid magnitude processing with fractions and decimals may occur by mapping symbolic components onto common amodal mental representations of rational numbers. Al